Original articlesBreast tumorsBreast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen—To Offer More? (aTTom) trial
Breast tumors
Under a Creative Commons license
open access
BCI
molecular signature
predictive biomarker
early-stage breast cancer
endocrine benefit
Cited by (0)
J. M. S. Bartlett and D. C. Sgroi contributed equally as Joint first authors.
C. A. Schnabel and D. W. Rea contributed equally as Joint last authors.
Copyright © 2019 THE AUTHORS. Published by Elsevier Ltd.